# Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild,Moderate, or Severe Hepatic Insufficiency

> **NCT01916993** · PHASE1 · COMPLETED · sponsor: **Neurocrine Biosciences** · enrollment: 24 (actual)

## Conditions studied

- Safety, Tolerability, and PK of NBI-98854 in Hepatically Impaired Subjects

## Interventions

- **DRUG:** NBI-98854 50 mg capsule

## Key facts

- **NCT ID:** NCT01916993
- **Lead sponsor:** Neurocrine Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2014-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01916993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01916993, "Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild,Moderate, or Severe Hepatic Insufficiency". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01916993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*